Novartis said Friday it has pulled its irritable bowel treatment Zelnorm (tegaserod maleate) off the US market after new clinical data showed an increased risk of cardiovascular events in patients ...

treatment for irritable bowel syndrome, is being taken off the market because it can increase the risk of heart attacks, stroke and chest pain associated with heart disease. Novartis agreed to pull ...

The U.S. Food and Drug Administration has asked Novartis to stop selling its chronic constipation drug Zelnorm after combining 29 clinical studies turned up an increased cardiovascular risk. The ...

Novartis pulled bowel drug Zelnorm from U.S. shelves on Friday at the request of regulators because clinical trial data indicated a possible link to heart attacks and strokes. The move is a body blow ...

ZURICH, April 2 (Reuters) - Shares in Novartis fell over three percent on Monday after the Swiss drugmaker cut its 2007 sales forecast when it withdrew its bowel drug Zelnorm from U.S. shelves.

WASHINGTON – Swiss pharmaceutical maker Novartis AG will stop selling a drug to relieve constipation after it was linked to a higher chance of heart attack, stroke and worsening heart chest pain that ...

Goodbye cruel world. Novartis is pulling the irritable bowel med Zelnorm off the market almost completely, saying it will supply the drug only for emergency use. And even in emergencies, Zelnorm will ...

High-profile, quick-growing IBS drug shelved because of cardio risks. FDA has asked Novartis to pull Zelnorm (tegaserod) from the market five years after its approval, eliciting a swift and surprised ...

Novartis ' Zelnorm, approved by U.S. regulators in July, could well reach annual sales of $1 billion or more. But in order for that to happen, Novartis has to convince gun-shy doctors that the drug is ...